Ruxolitinib formulation for reduction of itch in atopic dermatitis

A method of treating moderate atopic dermatitis in a human patient in need thereof comprising:

• administering to the human patient's skin a topical formulation, comprising 1.5% (w/w) on a free base basis of ruxolitinib, or a pharmaceutically acceptable salt thereof, two times per day, and
• continuing the administration of the topical formulation for at least 8 weeks,
• wherein the human patient has a Body Surface Area (BSA) of atopic dermatitis involvement ranging from 3% to 20% at baseline,
• wherein the patient has an itch Numerical Rating Scale score of ≥4 at baseline,
• wherein the human patient is aged 12 or older,
• wherein the human patient achieves IGA treatment success (IGA-TS) as a score of 0 (clear) or 1 (almost clear) with ≥2 grade improvement from baseline at week 8 of the administration, and
• wherein the human patient achieves at least a 4 point reduction in itch Numerical rating Scale score from baseline at week 8 of the administration.